High materiality7/10
Guggenheim starts Ovid Therapeutics initiated with a Buy on OV329 potential
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim initiates OV329 coverage with a Buy rating; target $7; posted price $2.34.
- Guggenheim initiates OV329 with Buy; Target $7; Price $2.34; Guggenheim.
Key facts
- 01
Target: $7
- 02
Posted price: $2.34
- 03
Analyst firm: Guggenheim
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.